Kyphon Newswire (Page 2)

Comprehensive Real-Time News Feed for Kyphon. (Page 2)

Results 21 - 40 of 466 in Kyphon

  1. The organic gardener: Kent CrosbyRead the original story w/Photo

    Friday May 1 | Star Tribune

    Kent Crosby is a man of such wide-ranging interests that you can start a conversation about gardening and, next thing you know, you're talking about solar energy or geodesic domes or mythologist Joseph Campbell. To Crosby, they're all part of the larger philosophies that he has been developing since the late 1960s, and that guide his work as a carpenter and volunteer organic gardener at the Bakken Museum in south Minneapolis .

    Comment?

  2. Medtronic Initiates Study Evaluating Potential of Combination of...Read the original story

    Thursday Apr 30 | PressReleasePoint

    Enrollment Underway in the U.S. for Groundbreaking Study Involving Three Medtronic Devices: Arctic Front Advance Cryoballoon, Symplicity Spyral & Reveal LINQ ICM DUBLIN - April 30, 2015 - Medtronic plc today announced the start of a clinical study using Medtronic technologies to determine whether paroxysmal and persistent atrial fibrillation can be treated with a combination of two ablation procedures targeting different anatomical locations - specifically, the pulmonary veins and the renal arteries. Study patients will also receive an implantable cardiac monitor to track their heart rhythm on an automatic and continuous basis.

    Comment?

  3. Endurant AAA Stent Graft System from Medtronic Delivers Consistently...Read the original story

    Wednesday Apr 29 | PressReleasePoint

    Analysis of ENGAGE Registry Patients Presented at Charing Cross International Symposium LONDON -- April 29, 2015 -- For endovascular repair of abdominal aortic aneurysms, the Endurant AAA stent graft system from Medtronic plc delivered consistently strong results in patients with short and standard neck lengths who were enrolled in the global ENGAGE registry -- the largest contemporary database on the performance of a single company's stent grafts in real-world clinical practice. Prof.

    Comment?

  4. FDA: Medtronic must stop most sales of Synchromed drug pumpsRead the original story w/Photo

    Monday Apr 27 | Worcester Telegram & Gazette

    The Food and Drug Administration says Medtronic must stop most sales of its implantable drug pumps after years of uncorrected problems. The FDA has filed a court order against Medtronic that says the medical device giant must halt most production and distribution of its Synchromed II drug pumps, which are implanted devices used to treat patients with cancer, chronic pain and severe muscle spasms.

    Comment?

  5. Medtronic Starts Clinical Study of Endurant Evo AAA Stent Graft...Read the original story

    Monday Apr 27 | PressReleasePoint

    Principal Investigators Perform First Implant of Investigational Medical Device Designed to Expand Applicability of Minimally Invasive Alternative to Open Surgical Repair DUBLIN -- April 27, 2015 -- Medtronic plc recently began a clinical study to evaluate the safety and effectiveness of the Endurant Evo AAA stent graft system, an investigational medical device designed to expand the applicability of a minimally invasive alternative to open surgical repair for the treatment of abdominal aortic aneurysms. Based on the market-leading Endurant platform, the Endurant Evo AAA stent graft system features an evolved design that aims to simplify the implant procedure and increase patient customization options.

    Comment?

  6. Medtronic Announces Consent Decree with FDA for the Synchromed Drug...Read the original story

    Monday Apr 27 | PressReleasePoint

    Agreement Provides a Path to Resolution with Continued Patient Access DUBLIN - April 27, 2015 - Medtronic plc announced today that it has reached agreement on the terms of a consent decree with the U.S. Food and Drug Administration specific to the company's SynchroMedA drug infusion system and the Neuromodulation quality system. The agreement is subject to approval by the U.S. District Court for the District of Minnesota.

    Comment?

  7. FDA limits sales of Medtronic device made in the Twin CitiesRead the original story w/Photo

    Monday Apr 27 | Business Journal

    Medtronic won't be able to make, design or distribute new Syncromed II systems except under certain circumstances until the FDA determines the company has met requirements outlined in a consent decree. Medtronic won't be able to sell its Synchromed II infusion pump system except under limited circumstances, according to terms of a settlement reached with the Food and Drug Administration .

    Comment?

  8. FDA files consent decree against Medtronic for "repeatedly failing to correct violations"Read the original story w/Photo

    Monday Apr 27 | Business Journal

    Medtronic Inc. has reached an agreement on the terms of a consent decree with the U.S. Food and Drug Administration. Officials with Minneapolis-based Medtronic Inc. said the company has reached an agreement on the terms of a consent decree with the U.S. Food and Drug Administration regarding its SynchroMed drug infusion system and the Neuromodulation quality system.

    Comment?

  9. Minnesota saw a brisk pace for corporate deals in the first quarterRead the original story w/Photo

    Sunday Apr 26 | Star Tribune

    When Norwest Equity Partners this month raised a record $2.4 billion to invest in promising private companies, it was just the latest evidence that confidence is back. "Things have been good-not-great in terms of the economy," said Tim DeVries, veteran managing general partner at Norwest Equity Partners .

    Comment?

  10. SapientNitro helps digital advertising take on a greater marketing roleRead the original story w/Photo

    Saturday Apr 25 | Star Tribune

    When Adrian Slobin opened the Minneapolis office of the Boston-based ad agency SapientNitro, he was one of three staffers servicing the account of one client. But that one client was Target , and Slobin's assignment was to bring the retailing giant into the digital age.

    Comment?

  11. MN: Run Commuting On the Rise in the Twin CitiesRead the original story w/Photo

    Friday Apr 24 | Mass Transit

    April 24--Most people grab their keys, lunch or maybe a travel mug of coffee before dashing off to work each morning. Jeff Metzdorff simply dashes off.

    Comment?

  12. Twin Cities 'run-commuters' are besting the rat raceRead the original story w/Photo

    Apr 23, 2015 | Star Tribune

    No car, transit pass or bicycle necessary - just a well-hewn pair of running shoes and a plan for cleanup upon arrival on the job. Most people grab their keys, lunch or maybe a travel mug of coffee before dashing off to work each morning.

    Comment?

  13. Medtronic Announces European Approval of the First and Only Full-Body ...Read the original story

    Apr 22, 2015 | PressReleasePoint

    Updated Labelling Allows Greater Patient Access to MRI DUBLIN - April 22, 2015 - Medtronic plc today announced that systems within its ActivaA portfolio of Deep Brain Stimulation Therapy neurostimulators have received European regulatory approval for MR Conditional full-body Magnetic Resonance Imaging .[*] The expanded approval for full-body MRI scans applies to all patients receiving a new system and to an estimated 13,000 people in Europe already receiving Medtronic DBS Therapy.* Medtronic DBS systems have previously been approved for MRI scans of the head only, under limited conditions. Medtronic DBS systems are not approved in the United States for full-body scans.

    Comment?

  14. Medtronic Begins Enrollment in Feasibility Study of Valiant...Read the original story

    Apr 21, 2015 | PressReleasePoint

    Investigational Device Enables Endovascular Repair of Aortic Aneurysms Encroaching on Left Subclavian Artery DUBLIN -- April 21, 2015 -- Medtronic plc today announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery . Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday.

    Comment?

  15. Increasing Competition Driven by Technological Shifts in U.S. Spinal...Read the original story

    Apr 21, 2015 | PRWeb

    ... competes. Medtronic gained the lead in both the VCF and motion preservation markets upon their acquisition of Kyphon in 2007. With the merger of DePuy and Synthes under the Johnson & Johnson family in 2012, this entity has become the number one ...

    Comment?

  16. Five years in, advocates for spinal cord injury research frustrated by House committee inactionRead the original story w/Photo

    Apr 20, 2015 | Star Tribune

    With an insider's eye, Hot Dish tracks the tastiest bits of Minnesota's political scene and keep you up-to-date on those elected to serve you. Contributors in Minnesota: Patrick Condon, J. Patrick Coolican, Patricia Lopez , Ricardo Lopez , Abby Simons, and Glen Stubbe .

    Comment?

  17. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Apr 20, 2015 | Business Wire

    S4T, through its Source4Teach... )--Waypoint Leasing , the largest independent global helicopter leasing company, today announced that it has acquired and placed on lease over 100 aircr... )--Ladenburg Thalmann Financial Services Inc. today announced that the Company sent the following annual letter to its shareholders from the Chairman o... )--Complete wheel set area of Delticom extends product range in European online stores with lots of new models and colour designs.the complete whe... )--Research and Markets has announced the addition of the "The Insurance Industry in Turkmenistan, Key Trends... )--+-FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code --Dois ensaios clA nicos globais publicados on-line na The New England Journal of Medicine e apresentados na European ... (more)

    Comment?

  18. Global Trials Show Addition of Medtronica s Solitairea Device Stent...Read the original story

    Apr 17, 2015 | Business Wire

    Global Trials Show Addition of Medtronic's Solitairea Device Stent Thrombectomy Procedure in Treatment of Acute Ischemic Stroke Improves Neurological Outcomes SWIFT PRIME and REVASCAT Confirm Findings of EXTEND-IA, ESCAPE and MR CLEAN, Support Addition of Solitaire Stent Thrombectomy to Current Standard of Care Research published online in The New England Journal of Medicine found that the addition of Medtronic's Solitairea device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke.

    Comment?

  19. Medtronic plans to develop stent graft system for treatment of thoracoabdominal aortic aneurysmsRead the original story w/Photo

    Apr 16, 2015 | Medical News

    The global leader in medical technology for endovascular aortic repair , Medtronic plc today announced that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with South Dakota-based Sanford Health. A concept for the novel system, which was described in the November 2014 issue of the Journal of Vascular Surgery , is currently being studied under a physician-sponsored investigational device exemption recently approved by the U.S. Food and Drug Administration .

    Comment?

  20. Medtronic to Develop Stent Graft System for Endovascular Repair of...Read the original story

    Apr 15, 2015 | Newswise

    The global leader in medical technology for endovascular aortic repair , Medtronic plc today announced that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with South Dakota-based Sanford Health. A concept for the novel system, which was described in the November 2014 issue of the Journal of Vascular Surgery , is currently being studied under a physician-sponsored investigational device exemption recently approved by the U.S. Food and Drug Administration .

    Comment?